Industry, physician and public health advocates agree that FDA's draft guidance on data needs for sunscreen ingredient GRASE determinations is overly focused on risks relative to benefits, potentially shortchanging consumers at a time of soaring skin-cancer rates.
FDA extended the comment deadline and was pointed about soliciting feedback regarding its draft guidance “Over-the-Counter Sunscreens: Safety and Effectiveness Data,” one of four sunscreen-themed guidances the agency...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?